Search

Search Constraints

You searched for: Author/Creator Nathanson, David

Search Results

1. BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI. (25th March 2021)

2. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Issue 9 (September 2017)

3. CBIO-03. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO FERROPTOSIS. (12th November 2021)

5. CBIO-25. INTEGRATED MOLECULAR AND BH3 PROFILING OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA. (9th November 2020)

6. CBIO-27. INTEGRATED FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA. (12th November 2021)

8. CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA. (11th November 2019)

9. Corrigendum to "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population–based case–control study" [Seizure: Eur. J. Epilepsy 59 (2018) 28–33]. (January 2021)

10. CTNI-14. EVALUATING METABOLIC ALTERATIONS IN PATIENTS WITH EGFR ACTIVATED RECURRENT GLIOBLASTOMA (RGBM) BY INHIBITING EGFR WITH OSIMERTINIB. (12th November 2021)